Market Overview

UPDATE: Jefferies Downgrades Express Scripts to Hold; Maturing Earlier

Related ESRX
JP Morgan Still Likes Express Scripts After Meeting With Management
Barron's Article 'Mischaracterizes' Express Scripts, Other Pharma Companies: J.P. Morgan
Express Scripts Is A Cash Machine (Seeking Alpha)

Jefferies reduced its rating on Express Scripts (NASDAQ: ESRX) from Buy to Hold and lowered its price target from $70 to $56.

Jefferies said, "We are downgrading ESRX to Hold from Buy after mgmt commented last night that 2013 Street EPS expectations (currently at 21% Y/Y growth) are overly aggressive. While we had anticipated ESRX's growth rate to decelerate after synergies from its Medco acquisition are realized, it appears that ESRX is reaching its maturity point quicker than most investors had expected."

Express Scripts closed at $27.46 on Monday.

Latest Ratings for ESRX

Oct 2015Leerink SwannMaintainsOutperform
Jun 2015OppenheimerInitiates Coverage onPerform
Jun 2015Deutsche BankMaintainsHold

View More Analyst Ratings for ESRX
View the Latest Analyst Ratings

Posted-In: JefferiesAnalyst Color Downgrades Pre-Market Outlook Analyst Ratings


Related Articles (ESRX)

View Comments and Join the Discussion!

Get Benzinga's Newsletters